Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label denosumab study in recurrent or unresectable giant cell tumor of bone
2006-006964-48Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by Amgen. Primary endpoint: Response rate among evaluable subjects. Started Mar 2007; status: completed.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on 2006-006964-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006964-48.